In the current environment, disruption and lack of predictability are the new norm. As we experienced in the COVID-19 pandemic, the force majeure clause is taking center stage at least for some companies. It is time to review your contracts to make sure you understand how these clauses apply.

Many understand the general concept of these clauses − a main tenet of most force majeure clauses is the impossibility of performance as a result of an unforeseen event that is out of the control of the party. In short, these clauses set out the situations where one party can be relieved of liability for non-performance during the pendency of this event that is out of the control of one of the parties. Typical examples are natural disasters, acts of war, or certain governmental actions.

However, how the clause is applied to your circumstances is often much more nuanced than the general concepts. Whether performance that is now more expensive or more challenging due to the current environment (e.g., tariffs or other events) amounts to a force majeure will depend on the governing law (domestic and international) applied, the force majeure clause terms and conditions themselves, and the totality of the particular circumstances. Navigating all of these issues in uncertain times is not something to be done at the last minute.

Photo of Bryan Brewer Bryan Brewer

H. Bryan Brewer III is a partner in Crowell & Moring’s Corporate, Privacy and Cybersecurity,  and International Trade groups.

Bryan is experienced in matters related to mergers and acquisitions, public securities, government contracts, intellectual property licensing and counseling, venture capital, export controls, and…

H. Bryan Brewer III is a partner in Crowell & Moring’s Corporate, Privacy and Cybersecurity,  and International Trade groups.

Bryan is experienced in matters related to mergers and acquisitions, public securities, government contracts, intellectual property licensing and counseling, venture capital, export controls, and general corporate governance issues that affect both for-profit and non-profit companies. Included in this experience is a focus on the intersection of corporate and cybersecurity and privacy as well as counseling with companies focused on digital transformation issues.

In addition to his corporate transactional practice, Bryan has over two decades of experience acting as special counsel to corporate trusts and trustees in the context of complex corporate transactions. Bryan has advised trusts in transactions relating to securitization, environmental, bankruptcy/liquidation, royalty, equipment, college/university, and the insurance verticals. He has advised and coordinated counseling on a wide range of matters impacting trusts and trustees, including general corporate and trust structuring matters, trust agreements, fiduciary duties, due diligence and trustee obligations under Delaware law, public securities and SEC filing obligations of publicly traded trusts, bankruptcy, litigation, tax, and matters relating to conflict of interest.

Bryan provides counseling for both public companies and privately held corporations on mergers and acquisitions, regulatory compliance, and securities issuances. He is experienced in providing advice on the corporate aspects of technology, life sciences, and government contracts. Bryan has counseled on digital strategy and technology in the autonomous vehicle, internet of things, artificial intelligence, and other transformative technology verticals. He also has advised emerging research-based companies with respect to the legal issues associated with the development of vaccines (including vaccines based on virus-like particles) and discovery of small molecules targeting emerging infectious agents, biodefense companies specializing in the development and commercialization of medical countermeasures against chemical and biological threats, and foundations focusing on biomedical research projects bringing the public sector (NIH) and the private sector (pharmaceutical, biotech, and other companies, foundations, and academia) together to solve persistent health challenges. Bryan’s experience involves counseling with respect to awards, RFPs, solicitations, teaming agreements, joint venture agreements, subcontracts, intellectual property, and licensing issues and positioning with respect to the National Institutes of Health (NIH), U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Health and Human Services (DHHS), Biomedical Advanced Research and Development Authority (BARDA), and other governmental agencies.

He is also experienced in providing corporate/business counseling and strategic advice for rapidly expanding start-up and pre-IPO companies. He has clients in a number of sectors including government contractors, energy, life sciences, technology, telecommunications, media and the financial markets. He has also worked on numerous matters related to International Traffic in Arms Regulations (ITAR), Export Administration Regulations (EAR), Committee on Foreign Investment in the United States (CFIUS) and regulatory and export compliance matters generally. He also counsels clients on transactional aspects of intellectual property rights and strategies and has experience in formulating, negotiating and implementing intellectual property licensing agreements, technology transfer programs, technology acquisitions, and copyright and trade secret protection programs.

Bryan has deep experience in working with trade associations on their transactional and corporate challenges and transactions. He has acted as outside counsel on numerous corporate matters and transactions for trade associations. Bryan has counseled numerous non-profit corporations on formation, licensing and related contract and intellectual property issues in a variety of industries. Bryan has authored numerous articles and frequently speaks on such topics as mergers & acquisitions, securities, venture capital, intellectual property, export controls and other emerging business issues.